Serum CD5L Responds Positively to Selenium and Coenzyme Q

Urban Alehagen, Jan O Aaseth, Trine B Opstad, Anders Larsson, Sabrina Asaad, Lutz Schomburg, Jan Alexander

Abstract read

In one paragraph

Article in Antioxidants (Basel, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Urban AlehagenDivision of Cardiovascular Medicine, Department of Medical and Health Sciences, Linköping University, 581 85 Linköping, Sweden.

Jan O AasethDepartment of Research, Innlandet Hospital Trust, 2380 Brumunddal, Norway.ORCID 0000-0002-7518-5703

Trine B OpstadOslo Center for Clinical Heart Research-Laboratory, Department of Cardiology, Oslo University Hospital Ullevål, 0450 Oslo, Norway.

Anders LarssonDepartment of Medical Sciences, Uppsala University, 751 85 Uppsala, Sweden.ORCID 0000-0003-3161-0402

Sabrina AsaadInstitut für Experimentelle Endokrinologie, Charité-Universitätsmedizin Berlin, 10115 Berlin, Germany.

Lutz SchomburgInstitut für Experimentelle Endokrinologie, Charité-Universitätsmedizin Berlin, 10115 Berlin, Germany.ORCID 0000-0001-9445-1555

Jan AlexanderNorwegian Institute of Public Health, 0213 Oslo, Norway.ORCID 0000-0002-6381-5720

Funding

County council of Östergötland n/aDeutsche Forschungsgemeinschaft LocoTact CRC/TR296Linköping University n/a

6 · The paper itself

Abstract

The Cluster of Differentiation 5-like protein (CD5L) is produced by tissue-resident macrophages. It is an innate immune mediator protein with a multitude of functions, such as binding of invading microorganisms and oxidised LDL, and it is associated with clinical conditions, i.e., atherosclerosis and inflammation. The circulating CD5L level has been reported to correlate to selenium status and thyroid hormone activity. In order to test this hypothesis, we analysed CD5L in serum samples from a randomized controlled trial (RCT) with selenium and coenzyme Q

Indexed as

CD5Lelderlyquality-of-lifeseleniumsupplementationthyroid hormones

Identifiers

PMID40227412

DOI10.3390/antiox14030366

PMCPMC11939726

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.